One year of PSA test results can lead to 10%-20% of men being misclassified as having a high risk of prostate cancer progression.
Modalities under investigation include laser ablation, hemiablative seed implantation, and results are promising.
For patients with metastatic disease receiving systemic treatment, a high BMI was found to improve overall survival.
Biochemical recurrence-free and metastasis-free survival can be achieved.
The trend is due mostly to an increasing incidence of visits by women.
The finding is based on a study of men with low-risk prostate cancer on active surveillance.
Partial or radical nephrectomy improves patients' survival odds, data show.
The trend toward increasing use of percutaneous nephrolithotomy is more pronounced among women than men.
MRI-demonstrated tumors at baseline associated with a higher risk of radiologic progression.
The procedure may be particularly useful in treatment men with prostates larger than 100 cc.
Recipients older than 65 had rates of delayed graft function and graft loss at one year similar to those of younger recipients.
The absence of cancer on a confirmatory biopsy is associated with a lower risk of volume-related, but not grade-related progression.
Increasing the number of prostate biopsy cores from 12 to 20 did not increase the likelihood or severity of complication.
In patients with muscle-invasive bladder cancer, those with bladder neck or multiple tumors are more likely to experience recurrent intravesical tumors.
New findings raise questions about PSA screening criteria.